25 related articles for article (PubMed ID: 912564)
1. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
Novikov AI
Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
[No Abstract] [Full Text] [Related]
2. Effect of hemodialysis membrane type on parathyroid hormone removal.
Kudlac H; Fielding AM; Williams AJ
Miner Electrolyte Metab; 1994; 20(5):245-9. PubMed ID: 7700210
[TBL] [Abstract][Full Text] [Related]
3. Anaphylatoxin formation during hemodialysis: effects of different dialyzer membranes.
Chenoweth DE; Cheung AK; Henderson LW
Kidney Int; 1983 Dec; 24(6):764-9. PubMed ID: 6609269
[TBL] [Abstract][Full Text] [Related]
4. Efficiency of three different hemodialysis membranes for plasma porphyrin removal.
Fontanellas A; Herrero JA; Moran MJ; Coronel F; Sepulveda P; Barrientos A; Enriquez De Salamanca R
Am J Kidney Dis; 1995 Jan; 25(1):30-3. PubMed ID: 7810529
[TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of intact parathyroid hormone adsorption by different dialysis membranes during hemodialysis.
Balducci A; Coen G; Manni M; Perruzza I; Fassino V; Sardella D; Grandi F
Artif Organs; 2004 Dec; 28(12):1067-75. PubMed ID: 15554934
[TBL] [Abstract][Full Text] [Related]
6. Hemodialysis versus cross hemodialysis in experimental hepatic coma.
Opolon P; Lavallard MC; Huguet C; Bidallier M; Granger A; Gallot D; Bloch P
Surg Gynecol Obstet; 1976 Jun; 142(6):845-53. PubMed ID: 936027
[TBL] [Abstract][Full Text] [Related]
7. Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone.
Fournier AE; Arnaud CD; Johnson WJ; Taylor WF; Goldsmith RS
J Clin Invest; 1971 Mar; 50(3):599-605. PubMed ID: 5545122
[TBL] [Abstract][Full Text] [Related]
8. Influence of immunoheterogeneity of circulating parathyroid hormone on results of radioimmunoassays of serum in man.
Arnaud CD; Goldsmith RS; Bordier PJ; Sizemore GW
Am J Med; 1974 Jun; 56(6):785-93. PubMed ID: 4133939
[No Abstract] [Full Text] [Related]
9. Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease.
Hruska KA; Kopelman R; Rutherford WE; Klahr S; Slatopolsky E; Greenwalt A; Bascom T; Markham J
J Clin Invest; 1975 Jul; 56(1):39-48. PubMed ID: 1141439
[TBL] [Abstract][Full Text] [Related]
10. Measurement of the transmittance coefficient spectrum of Cuprophan and RP69 membranes: applications to middle molecule removal via ultrafiltration.
Green DM; Antwiler GD; Moncrief JW; Decherd JF; Popovich RP
Trans Am Soc Artif Intern Organs; 1976; 22():627-36. PubMed ID: 951881
[TBL] [Abstract][Full Text] [Related]
11. Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis.
Bouillon R; Verberckmoes R; Moor PD
Kidney Int; 1975 Jun; 7(6):422-32. PubMed ID: 169419
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of dialysis with cuprophan versus polyacrylonitrile membranes on plasma immunoreactive parathyroid hormone levels in patients on chronic hemodialysis.
Gueris J; Fournier A; Sebert JL; De Fremont JF; Ferriere C; Covoet B; Quichaud J
Calcif Tissue Res; 1977 May; 22 Suppl():434-8. PubMed ID: 912564
[No Abstract] [Full Text] [Related]
13. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
Akiba T
Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
